Posted: 2024-05-14
Translational Breast Cancer Research is accepted for indexing in PubMed/PubMed Central (PMC)
On May 9, 2024, we received an official notice from the PubMed office that Translational Breast Cancer Research had been accepted for indexing by PubMed/PubMed Central (PMC), a free digital archive database of full-text journal literature in biomedical and life sciences. All articles published since 2022, beginning with Vol 3, will be fully indexed in PMC and accessible via PubMed, a search engine/database of biomedical citations and abstracts.
Posted: 2024-03-25
TBCR is officially indexed by Emerging Sources Citation Index (ESCI)
On March 20, 2024, a confirmation letter reached the editorial office of Translational Breast Cancer Research (TBCR) that the journal met the selection criteria necessary to be included in the Emerging Sources Citation Index. Articles published in TBCR since 2020, beginning with Vol 1, will be included in Emerging Sources Citation Index.
Posted: 2024-01-11
Annual Report of TBCR (2023)
We are pleased to share with you the 2023 annual report of Translational Breast Cancer Research (TBCR).
Posted: 2023-03-15
Full implementation of transparent peer review at Translational Breast Cancer Research (TBCR)
With a commitment to openness and accountability, and to increase the level of transparency throughout our peer review process, our editorial office has decided to fully implement the transparent peer review (TPR) process for all new submission from March 15, 2023.
Posted: 2023-01-31
Welcome to join us at the 18th St. Gallen International Breast Cancer Conference 2023, Vienna, Austria, 15 - 18 March!
The 18th St. Gallen International Breast Cancer Conference 2023 will be held in Vienna, Austria this year during 15-18 March.
Posted: 2023-01-11
Annual Report of TBCR (2022)
We are pleased to share with you the 2022 annual report of Translational Breast Cancer Research (TBCR).
Posted: 2022-01-13
Annual Report of TBCR (2021)
We are pleased to share with you the 2021 annual report of Translational Breast Cancer Research (TBCR).
Posted: 2021-11-05
Translational Breast Cancer Research (TBCR) is now a member of Committee on Publication Ethics (COPE)
Starting from July 2021, AME Publishing Company is formally recognized a publisher member of Committee on Publication Ethics (COPE) and over 60 AME-published journals become a member of Committee on Publication Ethics (COPE), as part of AME’s commitment to best practice in scholarly publishing. Translational Breast Cancer Research (TBCR) is among the list of COPE membership.
Posted: 2021-01-18
2020 Annual Report of TBCR
Greetings from the TBCR Editorial Office! We wish you a happy and fruitful 2021!
Posted: 2020-04-29
AME entered an official partnership with Publons to enhance wide-ranging recognition for reviewers
AME Publishing Company entered an official partnership with Publons, a product of Clarivate Analytic Company (which owns Web of Science, EndNote, ScholarOne, among many others), as of April 2020.
1 - 10 of 10 Items